又高又胖,前列腺癌的发生风险升高!

2017-07-14 MedSci MedSci原创

近期,来自英国牛津大学的一项研究探究了身高、肥胖和前列腺癌等级之间的关系。研究数据来自欧洲癌症和营养的前瞻性调查,包括141896名来自丹麦、意大利、德国、希腊、荷兰、西班牙、瑞典、和英国的参与者,平均年龄是52岁。在这些参与者中,共有7024名前列腺癌患者,其中726名患者为高级别前列腺癌患者,1388名为晚期前列腺癌患者,此外,还有934名前列腺癌患者死亡。对数据进行分析后,研究小组得出结论,

近期,来自英国牛津大学的一项研究探究了身高、肥胖和前列腺癌等级之间的关系。

研究数据来自欧洲癌症和营养的前瞻性调查,包括141896名来自丹麦、意大利、德国、希腊、荷兰、西班牙、瑞典、和英国的参与者,平均年龄是52岁。

在这些参与者中,共有7024名前列腺癌患者,其中726名患者为高级别前列腺癌患者,1388名为晚期前列腺癌患者,此外,还有934名前列腺癌患者死亡。

对数据进行分析后,研究小组得出结论,身高与前列腺癌发生的总风险无关。

然而,高级别前列腺癌以及前列腺癌死亡与身高有关:每额外加10厘米的高度,风险分别增加了21%和17%。

但是,身高与前列腺癌相关的因素却尚不清楚。

最后,研究小组还指出,BMI与前列腺癌之间的关系:较高的BMI与更高级别肿瘤的发生风险相关,以及前列腺癌死亡的风险增加相关。

在老年男性中,腰围被认为是一种比BMI更好的测量肥胖的方法,且研究已发现,腰围每增加10厘米,前列腺癌的死亡风险增加18%,高级别癌症的风险增加13%。

与肥胖有关风险增加可能是由于肥胖男性激素水平的变化,而这反过来又可能增加患前列腺癌的风险。然而,前列腺癌差异的部分原因或是由于肥胖男性前列腺癌检测的差异所致。

原始出处:

Higher risk of aggressive prostate cancer in taller and heavier men. MNT, 14 July 2017.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=222992, encodeId=906822299280, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Sun Jul 16 23:00:33 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222517, encodeId=19db22251eb0, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sat Jul 15 09:44:36 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222384, encodeId=76b82223841d, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sat Jul 15 02:07:31 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222352, encodeId=cf5c2223528f, content=真的还是假的a, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Sat Jul 15 00:11:19 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222334, encodeId=5c6c2223341b, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Fri Jul 14 23:00:07 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222317, encodeId=f35022231e37, content=看看了解了, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Fri Jul 14 21:30:42 CST 2017, time=2017-07-14, status=1, ipAttribution=)]
    2017-07-16 luominglian113

    学习了谢谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=222992, encodeId=906822299280, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Sun Jul 16 23:00:33 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222517, encodeId=19db22251eb0, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sat Jul 15 09:44:36 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222384, encodeId=76b82223841d, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sat Jul 15 02:07:31 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222352, encodeId=cf5c2223528f, content=真的还是假的a, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Sat Jul 15 00:11:19 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222334, encodeId=5c6c2223341b, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Fri Jul 14 23:00:07 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222317, encodeId=f35022231e37, content=看看了解了, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Fri Jul 14 21:30:42 CST 2017, time=2017-07-14, status=1, ipAttribution=)]
    2017-07-15 ylzr123

    好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=222992, encodeId=906822299280, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Sun Jul 16 23:00:33 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222517, encodeId=19db22251eb0, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sat Jul 15 09:44:36 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222384, encodeId=76b82223841d, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sat Jul 15 02:07:31 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222352, encodeId=cf5c2223528f, content=真的还是假的a, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Sat Jul 15 00:11:19 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222334, encodeId=5c6c2223341b, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Fri Jul 14 23:00:07 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222317, encodeId=f35022231e37, content=看看了解了, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Fri Jul 14 21:30:42 CST 2017, time=2017-07-14, status=1, ipAttribution=)]
    2017-07-15 130****4638

    学习了受益匪浅

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=222992, encodeId=906822299280, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Sun Jul 16 23:00:33 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222517, encodeId=19db22251eb0, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sat Jul 15 09:44:36 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222384, encodeId=76b82223841d, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sat Jul 15 02:07:31 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222352, encodeId=cf5c2223528f, content=真的还是假的a, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Sat Jul 15 00:11:19 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222334, encodeId=5c6c2223341b, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Fri Jul 14 23:00:07 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222317, encodeId=f35022231e37, content=看看了解了, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Fri Jul 14 21:30:42 CST 2017, time=2017-07-14, status=1, ipAttribution=)]
    2017-07-15 飛歌

    真的还是假的a

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=222992, encodeId=906822299280, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Sun Jul 16 23:00:33 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222517, encodeId=19db22251eb0, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sat Jul 15 09:44:36 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222384, encodeId=76b82223841d, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sat Jul 15 02:07:31 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222352, encodeId=cf5c2223528f, content=真的还是假的a, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Sat Jul 15 00:11:19 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222334, encodeId=5c6c2223341b, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Fri Jul 14 23:00:07 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222317, encodeId=f35022231e37, content=看看了解了, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Fri Jul 14 21:30:42 CST 2017, time=2017-07-14, status=1, ipAttribution=)]
    2017-07-14 dhzzm

    学习了分享了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=222992, encodeId=906822299280, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Sun Jul 16 23:00:33 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222517, encodeId=19db22251eb0, content=好文,值得点赞!认真学习了,把经验应用于实践,为患者解除病痛。, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sat Jul 15 09:44:36 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222384, encodeId=76b82223841d, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=00501987275, createdName=130****4638, createdTime=Sat Jul 15 02:07:31 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222352, encodeId=cf5c2223528f, content=真的还是假的a, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Sat Jul 15 00:11:19 CST 2017, time=2017-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222334, encodeId=5c6c2223341b, content=学习了分享了, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387d1660055, createdName=dhzzm, createdTime=Fri Jul 14 23:00:07 CST 2017, time=2017-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=222317, encodeId=f35022231e37, content=看看了解了, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f31612316, createdName=xiaotaiyang1, createdTime=Fri Jul 14 21:30:42 CST 2017, time=2017-07-14, status=1, ipAttribution=)]
    2017-07-14 xiaotaiyang1

    看看了解了

    0

相关资讯

Tumour Biol:Tim-3作为前列腺癌药物作用靶点的分析

Tim-3(T细胞免疫球蛋白结构域和包含粘蛋白结构域分子3)是一个新发现的免疫调节蛋白,并且在免疫调控中具有重要作用。最近的证据表明Tim-3在许多肿瘤中差异性调控并且在作为药物作用靶点上具有潜力。最近,有研究人员调查了Tim-3在前列腺癌发展上的影响。利用流式细胞仪分析了Tim-3在外围CD4+T和CD8+T细胞的表达情况。分析了Tim-3表达与临床病例特性的关系。另外,研究人员还在大量的石蜡包

Sci Rep:癌症相关细胞迁移蛋白TSPAN1受雄激素控制并且它的表达上调可以增强前列腺癌细胞迁移

在前列腺癌症中,细胞迁移能力可以促使细胞侵入和细胞转移过程,并且是前列腺癌死亡率和发生率的一个主要起因。然而,在前列腺癌病人中,促进癌细胞迁移的机制到目前为止仍旧不是很清楚。之前的报道鉴定了一个与癌症相关的细胞迁移蛋白四次跨膜蛋白1(TSPAN1),并且在前列腺癌中是一个临床相关雄激素调控蛋白。最近,发现该机制的研究团队发现,TSPAN1可以由雄激素精确的诱导,并且在前列腺癌中与正常前列腺组织和良

Prostate Cancer P D:前列腺周脂肪炎症与高等级前列腺癌相关

肥胖是亚临床炎症的一种起因,并且与高等级前列腺癌(PC)增加的风险和不良治疗结果相关。然而,是否炎症在前列腺周白色脂肪组织(WAT)中发生,并且导致了关于PC侵入性的肥胖的负面作用仍旧不清楚。最近,有研究人员进行了一项单中心、代表性的研究。研究召集了那些新诊断为PC的并且经历根治性前列腺切除术的男性。主要目标是检查通过CD68免疫组化技术检测的类花冠结构的前列腺周WAT炎症的流行情况。次级目标是探

Cancer:预测长期肿瘤结果的2015年前列腺癌等级组确认研究

之前的研究制定了一个分5个等级的预后等级组(GG)系统从而简化对患有前列腺癌病人的风险分层,格林森得分≤6、3+4、4+3、8和9或者10被分别认为是GG 1到5。最近,研究人员调查了在一个平等的健康系统中,根治性前列腺切除术后,活检GG预测长期肿瘤结果的实用情况。研究人员查询了2005年到2015年的在退伍军人医院进行过前列腺切除术的男性的数据库,并利用Co模型检查了活检GG的预后能力。同时,研

Sci Rep:前列腺癌激素治疗后的指长比预后意义

指长比已经作为一种可追溯的非侵入性生物标记来检测产前暴露于雄性激素的假定的影响。在最近这些年,许多的学者们关注了2D:4D(第二足趾与第四足趾)与前列腺癌的关系。最近,有研究人员探索了在前列腺癌病人中,指长比所具有的预后意义。研究人员查阅了在他们的机构中,382名经历过激素治疗的前列腺癌病人的病况和生存情况。临床病理参数生存分析作为分类变量,并通过对数秩检验确定。根据Cox比例风险分析,R2D:4

2016 JUA循证临床实践指南:前列腺癌

2016年10月,日本泌尿外科协会(JUA)更新发布了日本前列腺癌指南,作为日本前列腺癌指南4年来的第一次更新版本,期内容涵盖了从前列腺癌的流行病学到股息治疗的广泛话题。